Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Trius to Present at the JMP Securities Healthcare Conference



Trius to Present at the JMP Securities Healthcare Conference

SAN DIEGO, July 8, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief
Executive Officer of Trius Therapeutics, will provide a corporate presentation
on Tuesday, July 9^th at 9:30 a.m. Eastern Time at the JMP Securities
Healthcare Conference at the St. Regis Hotel in New York.

A live webcast will be available through the Investor Relations page of the
Trius website at http://investor.triusrx.com/events.cfm. A webcast replay will
be available approximately two hours after the presentation and will be
archived for 30 days.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
serious infections. The Company's lead investigational drug, tedizolid
phosphate, is a novel antibiotic in Phase 3 clinical development for the
treatment of serious gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with
Bayer HealthCare for the development and commercialization of tedizolid
phosphate outside of the U.S., Canada and the European Union. In addition to
the Company's tedizolid phosphate clinical program, Trius has initiated
Investigational New Drug (IND) enabling studies for its Gyrase-B development
candidate with potent activity against Gram-negative bacterial pathogens
including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter
and Pseudomonas. For more information, visit www.triusrx.com.

CONTACT: Public Relations Contact:
         Laura Kempke/Stacey Holifield at MSLGROUP
         trius@mslgroup.com
         781-684-0770
        
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         sloren@westwicke.com
         443-213-0507
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement